Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D06SUS
|
|||
| Former ID |
DIB005204
|
|||
| Drug Name |
AZD-3043
|
|||
| Synonyms |
TD-4756; THRX-918661
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Anaesthesia [ICD-11: 9A78.6; ICD-9: 338] | Phase 1 | [1] | |
| Company |
Theravance Inc
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C19H29NO5
|
|||
| Canonical SMILES |
CCCOC(=O)CC1=CC(=C(C=C1)OCC(=O)N(CC)CC)OCC
|
|||
| InChI |
1S/C19H29NO5/c1-5-11-24-19(22)13-15-9-10-16(17(12-15)23-8-4)25-14-18(21)20(6-2)7-3/h9-10,12H,5-8,11,13-14H2,1-4H3
|
|||
| InChIKey |
QPUVKSKJCNGSGT-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 579494-66-9
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | GABA(A) receptor gamma-3 (GABRG3) | Target Info | Modulator | [2] |
| KEGG Pathway | Neuroactive ligand-receptor interaction | |||
| Retrograde endocannabinoid signaling | ||||
| GABAergic synapse | ||||
| Morphine addiction | ||||
| Nicotine addiction | ||||
| Reactome | Ligand-gated ion channel transport | |||
| GABA A receptor activation | ||||
| WikiPathways | SIDS Susceptibility Pathways | |||
| Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell | ||||
| Iron uptake and transport | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01086813) Phase I, Single Centre, Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD3043. U.S. National Institutes of Health. | |||
| REF 2 | AZD-3043: a novel, metabolically labile sedative-hypnotic agent with rapid and predictable emergence from hypnosis. Anesthesiology. 2012 Jun;116(6):1267-77. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.